|Bid||10.22 x 1000|
|Ask||10.24 x 900|
|Day's Range||10.11 - 11.23|
|52 Week Range||1.50 - 33.95|
|Beta (5Y Monthly)||-2.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2020 - Aug 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.75|
Humanigen, Inc., (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that the first patient has been dosed at the Emory University School of Medicine in Atlanta, Georgia as part of the in the ACTIV-5 "Big Effect Trial" (ACTIV-5/BET) evaluating lenzilumab with remdesivir, compared to placebo and remdesivir, in patients hospitalized with COVID-19. Lenzilumab is the Company’s lead product candidate and proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to optimize antibody properties.
Humanigen, Inc., (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, today announced that the Company’s management will present or participate in panel discussions at the following upcoming virtual investor conferences:
Shares of AbbVie were down 0.1% in trading on Tuesday after the National Institutes of Health said it is running a mid-stage clinical trial evaluating a monoclonal antibody it developed with the privately held Boehringer Ingelheim in combination with remdesivir as a COVID-19 treatment. Gilead Sciences Inc. received emergency use authorization for remdesivir as a treatment for some severely ill COVID-19 patients earlier this year, and there are several clinical trials underway testing its effectiveness in combination with other therapies. AbbVie and BI's drug, Skyrizi, received approval from the Food and Drug Administration last year as a treatment for some forms of plaque psoriasis. The NIH also said as part of the Phase, adaptive, randomized, double-blind, placebo-controlled trial it is testing Humanigen Inc.'s experimental monoclonal antibody lenzilumab in combination with remdesivir. The company's stock was down 0.6% on Tuesday. So far this year, AbbVie's stock is down 2.7%, shares of Humanigen hav soared 410.9%, and the S&P 500 is up 9.4%.